Journal Article

S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial

Tsuji, Akihito, Emi, Yasunori, Sekikawa, Takashi, Takeuchi, Masahiro, Gotoh, Masahiro, Moriwaki, Toshikazu, Komatsu, Yoshito, Hironaka, Shuichi, Nakajima, Takako Eguchi, Machida, Nozomu, Boku, Narikazu, Nishina, Tomohiro, Esaki, Taito, Matsumoto, Shigemi, Hyodo, Ichinosuke, Yamaguchi, Kensei, Bando, Hideaki, Sugimoto, Naotoshi, Baba, Hideo

2016

Overview

Although leucovorin enhances the efficacy of fluorouracil, the anti-tumour activity of S-1 and leucovorin and their combination with oxaliplatin for patients with advanced gastric cancer is unknown. We compared the activity and safety of S-1 plus leucovorin, S-1 plus leucovorin and oxaliplatin, and S-1 plus cisplatin as first-line chemotherapy for advanced gastric cancer. In this multicentre, randomised, open-label, phase 2 trial, we recruited chemotherapy-naive patients with unresectable or recurrent gastric cancer with measurable lesions aged 20 years or older from 25 general hospitals and specialist centres in Japan. Patients were randomly assigned (1:1:1) centrally to receive S-1 plus leucovorin (S-1 40–60 mg orally plus oral leucovorin 25 mg twice a day for 1 week, every 2 weeks), S-1 plus leucovorin and oxaliplatin (S-1 plus leucovorin and intravenous oxaliplatin 85 mg/m2 on day 1, every 2 weeks), or S-1 plus cisplatin (S-1 40–60 mg orally twice a day for 3 weeks, plus intravenous cisplatin 60 mg/m2 on day 8, every 5 weeks). Randomisation was done with the minimisation method using performance status (0 vs 1) and tumour stage (stage IV vs recurrent) as stratification factors. The primary endpoint was independently reviewed overall response in the full analysis set. This trial is registered with Japic CTI, number 111635. Between Oct 20, 2011, and Dec 17, 2012, we enrolled and randomly assigned 145 patients: 49 patients were assigned to S-1 plus leucovorin, 47 to S-1 plus leucovorin and oxaliplatin, and 49 to S-1 plus cisplatin. An objective response assessed by the independent review committee was achieved in 20 (43% [95% CI 28·3–57·8]) of the 47 patients in the S-1 plus leucovorin group, 31 (66% [50·7–79·1]) of the 47 patients in the S-1 plus leucovorin and oxaliplatin group, and 22 (46% [31·4–60·8]) of the 48 patients in the S-1 plus cisplatin group (Fisher's exact test, p=0·84 for S-1 plus leucovorin vs S-1 plus cisplatin, p=0·063 for S-1 plus leucovorin and oxaliplatin vs S-1 plus cisplatin, and p=0·038 for S-1 plus leucovorin and oxaliplatin vs S-1 plus leucovorin). The most common grade 3–4 adverse events were neutropenia (three [6%] of 48 patients in the S-1 plus leucovorin group vs 12 [26%] of 47 patients in the S-1 plus leucovorin and oxaliplatin group vs 17 [35%] of 49 patients in the S-1 plus cisplatin group), decreased appetite (six [13%] vs 14 [30%] vs 12 [24%]), anaemia (five [10%] vs seven [15%] vs 13 [27%]), and hyponatraemia (two [4%] vs two [4%] vs nine [18%]). S-1 plus leucovorin and oxaliplatin was more active than S-1 plus leucovorin or S-1 plus cisplatin with acceptable toxic effects for patients with advanced gastric cancer. A phase 3 trial comparing S-1 plus leucovorin and oxaliplatin with S-1 plus cisplatin is underway. Taiho Pharmaceutical.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: 5-Fluorouracil / Adenocarcinoma - drug therapy / Adenocarcinoma - secondary / Aged / Anemia / Anemia - chemically induced / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Appetite loss / Cancer therapies / Chemotherapy / Cisplatin / Cisplatin - administration & dosage / Clinical trials / Colorectal cancer / Disease-Free Survival / Drug Combinations / Drug dosages / Feeding and Eating Disorders - chemically induced / Female / Gastric cancer / Hematology, Oncology and Palliative Medicine / Humans / Hyponatremia - chemically induced / Intravenous administration / Leucovorin - administration & dosage / Male / Medical prognosis / Metastasis / Middle Aged / Neoplasm Recurrence, Local - drug therapy / Neutropenia / Neutropenia - chemically induced / Organoplatinum Compounds - administration & dosage / Oxaliplatin / Oxonic Acid - administration & dosage / Stomach Neoplasms - drug therapy / Stomach Neoplasms - pathology / Survival Rate / Tegafur - administration & dosage / Treatment Outcome / Tumors